IBIO
IBIO
NASDAQ · Biotechnology

Ibio Inc

$1.71
+0.07 (+4.27%)
As of May 10, 10:47 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.37M
Net Income
-62,882,260
Gross Margin
38.4%
Profit Margin
-4,594.3%
Rev Growth
-40.3%
D/E Ratio
0.91
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 38.4% 38.4% 65.3% 65.3%
Operating Margin -4,650.5% -4,185.5% -16.4% -13.7%
Profit Margin -4,594.3% -4,364.5% -16.3% -13.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.37M 2.29M 19.24M 18.65M
Gross Profit 525.6K 880.4K 12.56M 12.17M
Operating Income -63,652,463 -95,958,486 -3,161,331 -2,555,901
Net Income -62,882,260 -94,797,376 -3,136,016 -2,526,921
Gross Margin 38.4% 38.4% 65.3% 65.3%
Operating Margin -4,650.5% -4,185.5% -16.4% -13.7%
Profit Margin -4,594.3% -4,364.5% -16.3% -13.6%
Rev Growth -40.3% -40.3% -5.9% +5.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 14.11M 14.11M 23.44M 21.95M
Total Equity 15.52M 15.52M 30.82M 33.89M
D/E Ratio 0.91 0.91 0.76 0.65
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -61,068,073 -97,177,000 -4,591,050 -4,236,243
Free Cash Flow -2,958,449 -2,128,422